Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

NCT00906841 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

75

Enrollment

OTHER

Sponsor class

Stopped completed recruitment of patients on 15 december 2010

Conditions

B-cell Lymphoma

Interventions

DRUG: 90Y-DOTA-hLL2

Sponsor

French Innovative Leukemia Organisation